

Company Fact Sheet

Personalized Cancer Immunotherapy

T-CURX

Pioneering next generation CAR-T cell cancer therapies

Company Profile

T-CURX GmbH is a private German early-stage biopharmaceutical company focused on identifying, developing and commercializing next generation CAR-T cell therapies in cancer indications of high medical need. The company's proprietary CAR-T technologies were developed in the labs of co-founder Prof. Michael Hudecek at Universitätsklinikum Würzburg, and are centered around a novel Sleeping Beauty (SB) Transposon system approach and are exclusively licenced to T-CURX. T-CURX has a development pipeline of 4 programs, the first product candidate is in clinical development (Ph I), the 2nd CAR-T program (novel target) in AML is ready for clinical trial application.

Proprietary IP-protected Technology Platform

T-CURX has built a strong IP portfolio consisting of 8 patent families that protect 3 core technologies:

- The novel CAR-T cell technology of T-CURX uses a scalable virus-free Sleeping Beauty Transposon gene transfer into patient's autologous T cells.
- Complementing technologies incorporated in T-CURX' CAR-T cell product pipeline comprise the proprietary MATCHMAKER technology for optimized potency and efficacy of CAR-T cell products and
- A proprietary ON/OFF safety-switch that allows the accurate control of the function of autologous CAR-T cells to manage patient safety after infusion.

The application of Transposon and Matchmaker technologies will overcome limitations of current CAR-T cell therapies and lower complexities and costs in manufacturing.

Market Challenges

Scalability, Cost & Turnaround

Efficacy

CAR-T cell toxicity

T-CURX proprietary solutions

I. Transposon-based Gene Transfer technology:

Transposon-based, virus-free gene transfer is already clinically validated, less complex in manufacturing (only DNA and mRNA required), resulting in lower COGS, short turnaround time and high scalability for larger cancer indications, incl. solid tumors

II. CAR-T MATCHMAKER Platform technology:

Maximizes anti-tumor efficacy by modular and flexible CAR spacer designed for optimal CAR to target binding. One requirement for effectively addressing solid tumor indications

III. ON/OFF Safety Switch technology:

Novel, 2-step safety switch to reversibly control the function of infused CAR-T cells in patients, and to delete CAR-T cells, if required (genetic delete switch still under development)

Management

Ulf Grawunder, PhD, CEO & Co-Founder
Michael Hudecek, MD, Co-Founder & CMO
Karl Schumacher, MD, CCO
Tom Loeser, CFO
Caroline Burger, PhD, Global Head BD
Jan Van den Brulle, PhD, Head R&D
Christian Söllner, General Counsel

Chairman of the Board

Hanspeter Gerber, PhD (US)

Scientific Advisory Board

Michael Hudecek, Prof., MD, Co-Founder (D)
Christoph Rader, Prof., PhD, Co-Founder (US)
Hermann Einsele, Prof., MD (D)
Cameron Turtle, Prof., MD, PhD (AU)

CAR-T specialists

Sabrina Prommersberger, PhD
Thomas Nerreter, PhD

Company at a glance

- T-CURX team with strong track record in clinical & business translation
- Sleeping Beauty transposon-based, virus-free gene transfer offers unparalleled scalability and efficiency
- Transposon & Matchmaker technologies are suitable to address solid tumors
- Safety Switch enables instant control over CAR-T function and potential side-effects
- One clinical asset already in Phase I trials
- 2nd CAR-T program (novel target) in AML is ready for clinical trial application
- Differentiated target portfolio with first- and best-in-class potential
- IP portfolio (Technology & Pipeline) of 8 patent families exclusive to T-CURX

T-CURX GmbH

Innovation and Founder Centre
Friedrich-Bergius-Ring 15
97076 Würzburg
Deutschland

P: +49-(0)-931-250-99-712

E: info@t-curx.com

W: www.t-curx.com



Jul 2023

Leadership and Board of Directors

T-CURX is led by the company's co-founder Ulf Grawunder, PhD, a serial entrepreneur with a proven track record in company building and deal making (founder and ex-CEO of NBE Therapeutics AG sold to Boehringer-Ingelheim for \$ 1,4 billion). His expertise is matched by a management team and Board of Directors with complimentary skills and established networks both in Europe and the US. T-CURX is also supported by its Scientific Advisory Board, a highly regarded network of leading experts that serve as external advisors and investigators on clinical trials.

Company Fact Sheet

Personalized Cancer Immunotherapy

T-CURX

Company Strategy

T-CURX will develop its own clinical candidates towards clinical proof-of-concept in several indications with the ultimate aim of advancing its proprietary technologies into development against additional cancer indications including solid tumors. This may ultimately make the transposon technology with its manufacturing process the future gold-standard in CAR-T cell therapy. In addition, T-CURX offers selected partners the opportunity to discover and develop additional therapies based on its technological platforms.

Partnerships and Grant-Funded Collaborations

Since its foundation in 2017, T-CURX secured non-dilutive funding in a total volume of over € 1.6 m through the award of several research grants. Amongst them are 2 German grants from BMBF and 3 EU grants (CARAMBA/RIA, imSAVAR/IMI, T2EVOLVE/IMI) with funding rates spanning from 50 % to 100 % for all EU grants. These consortia consist in total of more than 50 partners ranging from big pharma to academia and other institutions.

2023 – 2026 Development Plan and Value Inflection Points

T-CURX has established a differentiated target portfolio with first- and best-in-class potential and seeks funding for a 4 years' time frame to reach several critical value inflection points:

- **2023:** SLAMF7 Ph1 trial ongoing, CTA prepared for 2nd program in AML, pipeline programs 3,4 initiated
- **2024:** 2 Ph1 trials ongoing (SLAMF7 & Target 2 programs) 2 additional target programs IND ready
- **2025:** 2 Ph 2a trials ongoing (SLAMF7 1, Target2), 2 additional Ph 1 trials started (first early exit option)
- **2026:** 4 CAR-T programs in Ph 1/2a clinical trials, preparations for exit (M&A or IPO) underway

Investor Base and Financial Status

T-CURX' company runway is secured until Q2 2024 by strong commitments of existing shareholders, mostly European/US Single Family Offices. The company starts a fundraising campaign for a Preferred Series A Equity Financing Round with institutional European and US investors in 2023.

Recent Financial Highlights in the CAR-T Sector

- **June 2022, Cellpoint:** acquisition by Galapagos to accelerate access to next-generation cell therapies (€ 125m upfront and € 100m on milestones)
- **Sept 2022, Arsenal Biosciences:** \$ 220m Pref. Series B round, discovery collaboration with Genentech (\$ 70m upfront and undisclosed amount for R&D, development and commercial milestones)
- **March 2023, CARGO Therapeutics:** Spin-off of Stanford University, \$ 200m Series A financing for clinical development of CD19/CD22 dual CAR-T therapies
- **Aug 2023: Cellares:** \$ 255m Series C financing of Cell Therapy/CAR-T CDMO

T-CURX Recognition in the CAR-T Sector

- 2015: German M4 award in recognition of IP property base and business concept
- 2018: Horizon 2020 EU translational project CARAMBA for translation into Ph I clinical trials by utilizing proprietary virus-free transposon-based CAR-T technology in multiple myeloma
- 2021: Scientific advice meeting with German Paul-Ehrlich-Institute for T-CURX CAR-T cell program in Acute Myeloid Leukemia
- 2021: FDA approval for Breyanzi® marketed by Bristol Myers Squibb (Prof. Michael Hudecek co-inventor and author of key patent)

Active Pharma Players in the CAR-T Space:

